A Safety and Efficacy Study of MIM-D3 Ophthalmic Solution for the Treatment of Dry Eye

Completed · Phase 3 · Has a placebo group

Conditions studied: Dry Eye Syndromes

In brief

The purpose of this study is to assess the safety and efficacy of MIM-D3 Ophthalmic Solution compared with Placebo Ophthalmic Solution in treating the signs and symptoms of dry eye.

Key facts

Study ID

NCT01960010

Run by

Mimetogen Pharmaceuticals USA, Inc.

People needed

403

Starts

2013-10-01

Expected to finish

2014-08-01

Last updated by the study team

2019-08-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Be at least 18 years of age
• Provided written informed consent
• Have a reported history of dry eye
• Have a history of use or desire to use eye drops for dry eye

You may not qualify if…

• Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active ocular inflammation (e.g. follicular conjunctivitis) at Visit 1, or have been diagnosed with ocular rosacea, or any viral or bacterial disease of the cornea or conjunctiva, within the last 12 months
• Have any planned ocular and/or lid surgeries over the study period
• Have corrected visual acuity greater than or equal to +0.7 as assessed by Early Treatment of Diabetic Retinopathy Study (ETDRS) scale in both eyes at Visit 1
• Have an uncontrolled systemic disease
• Be a woman who is pregnant, nursing or planning a pregnancy
• Be a woman of childbearing potential who is not using an acceptable means of birth control; acceptable methods of contraception include: hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a diaphragm or condom; IUD; or surgical sterilization of partner. For non-sexually active females, abstinence may be regarded as an adequate method of birth control; however, if the subject becomes sexually active during the study, she must agree to use adequate birth control as defined above for the remainder of the study
• Have a known allergy and/or sensitivity to the test article or its components
• Have a condition or be in a situation which the investigator feels may put the subject at significant risk, may confound the study results, or may interfere significantly with the subject's participation in the study
• Be currently enrolled in an investigational drug or device study or have used an investigational drug or device within 45 days of Visit 1
• Be unable or unwilling to follow instructions, including participation in all study assessments and visits

Where it is running

• MIM-725 Investigational Site — Waterbury, Connecticut, United States
• MIM-725 Investigational Site — Lewiston, Maine, United States
• MIM-725 Investigational Site — Andover, Massachusetts, United States
• MIM-725 Investigational Site — Quincy, Massachusetts, United States
• MIM-725 Investigational Site — Memphis, Tennessee, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.